Innovative Therapeutics Biomarck Pharmaceuticals specializes in anti-inflammatory and immunological therapies targeting the MARCKS protein, presenting opportunities to collaborate with healthcare providers seeking novel treatments for conditions like ARDS and cancer.
Clinical Progress With ongoing Phase 2 trials and promising data released for its peptides, there is a clear window to engage with pharmaceutical partners and healthcare institutions interested in cutting-edge inflammatory disease solutions.
Growing Recognition Being recognized as the 2019 Colorado Manufacturer of the Year enhances credibility, enabling sales teams to leverage this recognition when establishing trust with potential clients and partners.
Funding & Revenue While the company's revenue is modest ($1M-$10M), its recent funding and active clinical pipeline suggest potential for expansion, making it attractive for investors and partners seeking emerging biotech opportunities.
Technological Edge Utilizing modern cloud and development technologies indicates a forward-thinking approach, which can appeal to research institutions and biotech firms interested in innovative partnerships and integration efforts.
$10B
$10B
$10B
$10B
$10B
$10B
$10B
$10B
$10B
$10B
$10BBiomarck Pharmaceuticals, Ltd. uses 8 technology products and services including Cloudflare CDN, Twemoji, Chart.js, and more. Explore Biomarck Pharmaceuticals, Ltd.'s tech stack below.
| Biomarck Pharmaceuticals, Ltd. Email Formats | Percentage |
| FLast@biomarck.com | 45% |
| F.Last@biomarck.com | 5% |
| FLast@biomarck.com | 45% |
| F.Last@biomarck.com | 5% |
Pharmaceutical ManufacturingNorth Carolina, United States11-50 Employees
Biomarck Pharmaceuticals, Ltd. is a clinical stage biotechnology company focused on treating patients with inflammatory and immunological diseases, using our platform of patent-protected peptides that have been developed to inhibit MARCKS. As a critical component of the inflammatory process, MARCKS is responsible for neutrophil aggregation at the site of inflammation and cytokine release.
Company Overview
Media & News
Funding & FinancialsBiomarck Pharmaceuticals, Ltd. has raised a total of $751K of funding over 4 rounds. Their latest funding round was raised on Feb 08, 2017 in the amount of $751K.
Biomarck Pharmaceuticals, Ltd.'s revenue is estimated to be in the range of $1M$10M
Funding & FinancialsBiomarck Pharmaceuticals, Ltd. has raised a total of $751K of funding over 4 rounds. Their latest funding round was raised on Feb 08, 2017 in the amount of $751K.
Biomarck Pharmaceuticals, Ltd.'s revenue is estimated to be in the range of $1M$10M
1-888-653-2347 
support@leadiq.com